Live feed08:30:00·30dPRReleasevia QuantisnowJohnson & Johnson's RYBREVANT FASPRO™ (amivantamab and hyaluronidase-lpuj) receives U.S. FDA Priority Review as potential first-in-class EGFR- and MET-targeted subcutaneous treatment for advanced head and neck cancerByQuantisnow·Wall Street's wire, on your screen.JNJ· Johnson & JohnsonHealth Care
